Epigallocatechin-3-gallate ameliorates liver injury secondary to Pseudomonas aeruginosa pneumonia

Int Immunopharmacol. 2022 Nov:112:109239. doi: 10.1016/j.intimp.2022.109239. Epub 2022 Sep 13.

Abstract

Pseudomonas aeruginosa is a dangerous pathogen causing nosocomial pneumonia. P. aeruginosa infection-induced liver damage is another fatal threat, and antibiotic treatment is not effective in relieving P. aeruginosa virulence-triggered damage. We here evaluated the protective effect of epigallocatechin gallate (EGCG), a substance that inhibits virulence of P. aeruginosa through quorum quenching, on liver damage secondary to P. aeruginosa infection. Mice were pretreated with EGCG (20, 40, and 80 mg/kg) for 3 days, and then infected with P. aeruginosa through intratracheal instillation to model acute pneumonia. The mice were sacrificed after 24 h of infection, and samples were harvested for subsequent analysis. EGCG significantly decreased the serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Histopathological changes of liver were significantly ameliorated by EGCG. It also significantly reduced oxidative stress that induced liver damage in P. aeruginosa infection, which relied not on the activation of the Nrf2-HO-1 pathway but on the upregulation of the activity of antioxidative enzymes. Then, the inflammatory response in the liver was tested. EGCG inhibited the release of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) by blocking the inflammation regulating signaling of the TLR4-myD88-NF-κB pathway. EGCG upregulated the activation of nuclear receptors to stronger the liver protective activity against P. aeruginosa infection. Conclusively, EGCG exhibited a significant hepatoprotective effective against P. aeruginosa infection.

Keywords: EGCG; Liver damage; PAO 1; TLR4-myD88-NF-κB pathway.

MeSH terms

  • Alanine Transaminase
  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Aspartate Aminotransferases
  • Catechin* / pharmacology
  • Catechin* / therapeutic use
  • Cytokines / metabolism
  • Interleukin-6 / metabolism
  • Liver / pathology
  • Liver Diseases* / microbiology
  • Mice
  • Myeloid Differentiation Factor 88 / metabolism
  • NF-kappa B / metabolism
  • Pneumonia, Bacterial* / complications
  • Pneumonia, Bacterial* / drug therapy
  • Pseudomonas Infections* / complications
  • Pseudomonas Infections* / drug therapy
  • Pseudomonas aeruginosa
  • Toll-Like Receptor 4 / metabolism
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Alanine Transaminase
  • Anti-Bacterial Agents
  • Aspartate Aminotransferases
  • Catechin
  • Cytokines
  • epigallocatechin gallate
  • Interleukin-6
  • Myeloid Differentiation Factor 88
  • NF-kappa B
  • Toll-Like Receptor 4
  • Tumor Necrosis Factor-alpha